Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

Beta blockers were associated with later appearance of motor symptoms and slower symptom worsening, but an outside expert ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Google has just released the Android 16 Beta 1 update for supported Pixel devices. Here's an overview of what's new in this ...

Specific protein receptors in the brain play a vital role in how neurons slow down or stop firing, making them targets for many disorders. Researchers have now constructed a detailed structural map of ...

The study of GLP1R variants shows associations with cardiometabolic traits and behavioral changes, highlighting indirect effects of GLP1RA on mental health.

Blarcamesine potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancementImpairment of autophagy ...

Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation without ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

Gluco6 is a dietary supplement crafted to support healthy blood sugar levels. Featuring a blend of natural ingredients backed ...

The beta test for Elden Ring Nightreign is scheduled for February 14 through 16, but only during select time periods. Step 1: Visit the official Elden Ring Nightreign site starting on January 10.

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...